Natick Firm Receives Stem Cell Patent
Parcell Laboratories, a Natick-based provider of stem cell therapeutics, announced it has received a patent on its Early Lineage Adult (ELA) stem cell platform.
The ELA platform, which is patented through 2028, will allow Parcell to provide a host of regenerative therapies for multiple diseases, according to Parcell founder and CEO Pamela Layton. It includes the technology of providing an isolated population of stem cells that exist in the synovial fluid (found in joint tissue), blood, and other tissues in the body and related therapeutic methods, according to the company.
The ELA platform is unique because the stem cells do not pose the same ethical controversies associated with embryonic stem cells and do not pose higher tumor-generating potential as embryonic stem cells do, according to Parcell. ELA cells also do not express the surface markers associated with other adult stem cells.
"The ELA stem cell platform has many potential therapeutic applications, and this patent validates our efforts and our future business plans. Our cellular platform, infrastructure and expertise will help make the promise of regenerative medicine a reality,” Layton said in a statement.
WBJ Web Partners
Most Recent
Most Recent
0 Comments